TKI Therapy in CML: Practical Considerations
This information was originally presented on September 20, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this activity, participants should be able to:
- Identify the challenges associated with the management of patients with CML
- Summarize the role of mutational analysis, management of side effects, and adherence to TKI therapy
Michael M. Millenson, MD
Fox Chase Cancer Center
Available Credit
- 0.50 Participation
- 0.54 Nurse
- 0.50 Pharmacist
- 0.50 Physician
Price
Cost:
$0.00
Required Hardware/software
To access this activity, users will need:
- A device with an Internet connection and sound playback capability
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader for certificate viewing/printing